Abbott Laboratories earnings calendar builds toward mid-July, shares on NYSE ahead of Q2 update

Abbott Laboratories has its next earnings release scheduled for July 16 before the US market open. With the stock trading on the NYSE and consensus estimates in place, investors get a clearer view of expectations for the medical devices and diagnostics group.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 16:10.

Abbott Laboratories (US0028241000) heads toward its next quarterly update with a firm date in the diary. The S&P 500 member plans to report second-quarter numbers on July 16 before the US market open, with New York investors watching the NYSE listing closely as consensus estimates solidify around the medical technology group. MarketBeat lists the Q2 earnings schedule and estimates.

What analysts currently expect

For the upcoming quarter, consensus points to adjusted earnings per share of roughly 1.14 US dollars, compared with an actual 1.15 dollars in the April 16 first-quarter report, when Abbott marginally beat expectations. The same source shows the recent EPS history and Q2 estimate.

In its latest guidance, Abbott forecasts 2026 sales growth between 6.5 and 7.5 percent and adjusted EPS in a range of 5.38 to 5.58 dollars, with the midpoint of 5.48 dollars reflecting about 0.20 dollars of dilution from the Exact Sciences acquisition. Zacks notes that the shares trade roughly 36 percent below their 52-week high after a pronounced year-to-date decline. Zacks outlines the guidance ranges and valuation backdrop.

How research houses view the stock

Bank of America Securities maintains a Neutral stance on Abbott, according to a mid-June update that left the rating unchanged. The assessment comes as the stock remains well below its prior peak, with investors weighing guidance credibility and acquisition-related dilution. MarketScreener summarizes the Bank of America view and other analyst opinions.

Zacks currently assigns Abbott a Rank 4 (Sell) and highlights that consensus estimates for 2026 and 2027 have been revised lower in recent months. The research house points to a weaker-than-expected respiratory season, integration of Exact Sciences and broader macro pressures as factors behind the underperformance versus the wider medical sector. The Zacks analysis details the estimate revisions and Rank.

The product behind the stock

Abbott Laboratories generates a large part of its revenue with its FreeStyle Libre line of glucose monitoring systems used by people with diabetes. The company recently announced CE marking for a dual glucose-ketone sensing technology designed to work with its Libre Duo and Libre Duo 10 Day systems for better metabolic monitoring. MarketScreener cites the CE marking announcement for the dual sensor technology.

Where the shares trade today

The Abbott Laboratories shares (US0028241000) most recently closed on the NYSE at 88.41 US dollars on 2026-06-18 at 15:59 Eastern Time, corresponding to roughly 76.66 euros on European quotation platforms at that point.

Key data on the Abbott Laboratories shares

• Company: Abbott Laboratories
• ISIN: US0028241000
• WKN: 850103
• Ticker: ABT
• Trading venue: NYSE
• Price (as of 2026-06-18, 15:59): 88.41 USD
• Market cap: around 153 billion USD (as of 2026-06-18)
• Sector / industry: Health care equipment and supplies / medical devices and diagnostics
• Index membership: S&P 500
• Next earnings date: 2026-07-16

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an invitation to buy or sell securities. Investors should conduct their own research and, where appropriate, consult a licensed financial adviser.